Oramed Pharmaceuticals Inc. (ORMP.TA)
ORMP.TA Stock Price Chart
Explore Oramed Pharmaceuticals Inc. interactive price chart. Choose custom timeframes to analyze ORMP.TA price movements and trends.
ORMP.TA Company Profile
Discover essential business fundamentals and corporate details for Oramed Pharmaceuticals Inc. (ORMP.TA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
13 Jul 2017
Employees
17.00
Website
https://www.oramed.comCEO
Nadav Kidron
Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's product portfolio includes ORMD-0801 Type 2, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes; ORMD-0801, Phase 2 oral insulin capsule for non-alcoholic steatohepatitis, a progressive liver diseases; and ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
ORMP.TA Financial Timeline
Browse a chronological timeline of Oramed Pharmaceuticals Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 6 Nov 2025
Earnings released on 14 Aug 2025
EPS came in at -ILA 0.14 matching the estimated -ILA 0.14.
Earnings released on 15 May 2025
EPS came in at -ILA 0.71 falling short of the estimated -ILA 0.04 by -1.80K%, while revenue for the quarter reached ILA 7.45M .
Earnings released on 26 Feb 2025
EPS came in at -ILA 0.07 matching the estimated -ILA 0.07.
Earnings released on 8 Nov 2024
EPS came in at -ILA 1.79 falling short of the estimated ILA 0.02 by -9.70K%.
Earnings released on 15 Aug 2024
EPS came in at ILA 0.83 surpassing the estimated ILA 0.04 by +2.10K%.
Earnings released on 10 May 2024
EPS came in at ILA 0.15 matching the estimated ILA 0.15.
Earnings released on 28 Feb 2024
EPS came in at -ILA 0.44 matching the estimated -ILA 0.44.
Earnings released on 10 Nov 2023
EPS came in at -ILA 0.31 surpassing the estimated -ILA 0.32 by +6.04%.
Earnings released on 11 Aug 2023
EPS came in at -ILA 0.11 surpassing the estimated -ILA 0.37 by +70.59%, while revenue for the quarter reached ILA 2.48M , missing expectations by -4.58%.
Earnings released on 12 May 2023
EPS came in at -ILA 0.16 surpassing the estimated -ILA 0.29 by +44.26%, while revenue for the quarter reached ILA 2.38M , missing expectations by -3.96%.
Earnings released on 6 Mar 2023
EPS came in at -ILA 0.22 surpassing the estimated -ILA 0.23 by +4.35%, while revenue for the quarter reached ILA 2.35M , missing expectations by -6.19%.
Earnings released on 10 Nov 2022
EPS came in at -ILA 0.18 surpassing the estimated -ILA 0.25 by +28.00%, while revenue for the quarter reached ILA 2.41M , missing expectations by -2.85%.
Earnings released on 10 Aug 2022
EPS came in at -ILA 0.27 falling short of the estimated -ILA 0.22 by -22.73%, while revenue for the quarter reached ILA 2.35M , missing expectations by -4.14%.
Earnings released on 12 May 2022
EPS came in at -ILA 0.27 falling short of the estimated -ILA 0.23 by -17.39%, while revenue for the quarter reached ILA 2.13M , missing expectations by -4.01%.
Earnings released on 11 Jan 2022
EPS came in at -ILA 0.22 falling short of the estimated -ILA 0.16 by -37.50%, while revenue for the quarter reached ILA 2.13M .
Earnings released on 24 Nov 2021
EPS came in at -ILA 0.21 falling short of the estimated -ILA 0.18 by -16.67%, while revenue for the quarter reached ILA 2.19M , missing expectations by -25.20%.
Earnings released on 14 Jul 2021
EPS came in at -ILA 0.17 surpassing the estimated -ILA 0.20 by +15.00%, while revenue for the quarter reached ILA 2.21M .
Earnings released on 13 Apr 2021
EPS came in at -ILA 0.17 matching the estimated -ILA 0.17, while revenue for the quarter reached ILA 2.18M .
Earnings released on 14 Jan 2021
EPS came in at -ILA 0.23 falling short of the estimated -ILA 0.14 by -64.29%, while revenue for the quarter reached ILA 2.24M .
Earnings released on 24 Nov 2020
EPS came in at -ILA 0.12 surpassing the estimated -ILA 0.21 by +42.86%, while revenue for the quarter reached ILA 2.30M .
ORMP.TA Stock Performance
Access detailed ORMP.TA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.